基因检测与糖尿病资料.ppt

* 脂联素ADIPOQ等位基因 对罗格列酮疗效的影响 Pharmaceuticals (Basel). 2010 Aug 1;3(8):2610-2646. * PGx与噻唑烷二酮类的疗效 ?首先,过氧化物体增殖激活受体-γ( PPAR-γ)基因变异有 heterozygous genotype (rs1801282; Pro12Ala)和 homozygous genotype (Pro12Pro). ?如携带Pro/Ala者,较携带 Pro/Pro者显著降低罗格列酮的禁食血糖水平和HbA1c水平;如携带Pro12Ala, 则PPAR-γ增加 7.2倍 Mol Diagn Ther. 2007;11(5):291-302 Pharmacogenomics 2007;8:917~931 * CYP2C8/SLCO1B1基因多态性 对罗格列酮疗效的影响 研究表明携带CYP2C8基因多态性者,可显著改变罗格列酮的PK,并提高疗效 ,而SLCO1B1 则否; Human Genomics 2008;3:7~16 * 小结:PGx与口服抗高血糖药 British Journal of Diabetes Vascular Disease 2011 11: 10 * 美国糖尿病协会2010年会重点研讨PGx与T2D的相关性 70th:PGx Abstracts from the American Diabetes Associations Annual Scientific Sessions July 07, 2010 investigating SNPs showing variable patient responses to commonly prescribed medications; and analyzing genetic risk for conditions that can heighten peoples chances of developing diabetes. * PGx抗高血糖药━主要关注三个基因多态性 1,针对药物ADME的OCT1和2C9/8/19 3A4; 2,针对药物受体的KCNJ11; 3,针对疾病发展的TCF7L2 * 防治糖尿病达标━我们的目的是什么?如何做得更好! Achieving Diabetes TargetsWhere are we, and how can we do better? Robert E. Ratner, MD MedStar Research Institute Georgetown University Medical School Washington, DC *  代结束语 Una Glamoclija professor: Genetic polymorphisms in diabetes: Influenceon therapy with oral antidiabetics  迄今资料显示,一系列基因影响着口服降糖药的疗效,为此,有关糖尿病个体化治疗的成绩与日俱增,特别是关注的焦点集中在如何保证剂量准确的领域,即防止因过量或不合理用药所致的低血糖! PGx的发展为改善糖尿病的预后提供了科学依据,今后将更深入研究发展。 Acta Pharm. 60 (2010) 387–406 * 根据您的基因而选用药物! 基因身份证 * 謝谢大家参与! * * It is important that we understand just what the impact of this condition is. Already diabetes accounts for up to three million deaths per year, mostly as a result of the cardiovascular complications of the disease. But it is also the leading cause of limb amputation and one of the leading causes of kidney failure and blindness. The direct costs of managing the disease are in excess of US$150 billion per annum but this does not account for